Nitroreductase Enzyme Applications in Cancer Therapy

Nitroreductase enzymes catalyse the reduction of nitroaromatic compounds to cytotoxic species and have emerged as powerful tools in targeted cancer therapy. By converting non-toxic prodrugs into active chemotherapeutics within tumours, these enzymes enable precise spatial control of drug activation, minimising systemic toxicity. Strategies such as gene-directed enzyme prodrug therapy (GDEPT) employ gene delivery vectors to express bacterial nitroreductases selectively in malignant tissues. Subsequent administration of nitroaromatic prodrugs triggers localised cell death and a bystander effect that extends cytotoxic metabolites to adjacent tumour cells. Advances in enzyme engineering guided by structural biology have yielded variants with enhanced substrate specificity and catalytic rates. Parallel developments in nanoparticle-based delivery and magnetic targeting integrate nitroreductases into hybrid platforms that combine diagnostic imaging and therapy. These collective efforts address limitations of conventional chemotherapy by improving prodrug activation efficiency, widening the range of suitable substrates and reducing off-target effects. Emerging applications extend beyond cell ablation to the synthesis of therapeutic small molecules, underscoring the global significance of nitroreductase-mediated approaches in precision oncology.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Nitroreductase Enzyme Applications in Cancer Therapy publication trend

The graph below shows the total number of articles in nitroreductase enzyme applications in cancer therapy across all publications each year (not limited to Nature Index journals).

Technical terms

Nitroreductase: A flavin-dependent enzyme that catalyses the reduction of nitro groups on aromatic or aliphatic substrates to nitroso, hydroxylamine or amine products.

Prodrug: An inert precursor molecule converted in vivo into an active drug by enzymatic or chemical processes.

Gene-directed enzyme prodrug therapy (GDEPT): A targeted cancer treatment strategy whereby genes encoding prodrug-activating enzymes are delivered to tumour cells prior to systemic administration of a non-toxic prodrug.

Bystander effect: The phenomenon by which cytotoxic metabolites generated in enzyme-expressing cells diffuse to and kill neighbouring non-transduced tumour cells.

Flavin mononucleotide (FMN): A redox-active cofactor bound by nitroreductases that mediates electron transfer during substrate reduction.

Catalytic promiscuity: The ability of an enzyme to catalyse multiple, mechanistically related chemical reactions on diverse substrates.

References

1. The Crystal Structure of Engineered Nitroreductase NTR 2.0 and Impact of F70A and F108Y Substitutions on Substrate Specificity. International Journal of Molecular Sciences (2023).
2. The dinitrobenzamide mustard prodrugs, PR-104A and SN27686, for use in a novel MNDEPT cancer prodrug therapy approach. Bioscience Reports (2023).
3. Exploring the Substrate Scope and Catalytic Promiscuity of Nitroreductase‐Like Enzymes. Advanced Synthesis & Catalysis (2024).